3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
10
Neoplasm Metastasis
9
Carcinoma, Non-Small-Cell Lung
5
Recurrence
3
Prostatic Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Ovarian Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non Castrate Metastatic Prostate Cancer
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Interventions
pembrolizumab
2
fludarabine
2
Radiosurgery
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
Carboplatin
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
regorafenib
1
pazopanib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
ibrutinib
1
grapiprant
1
fludarabine phosphate
1
famitinib
1
encorafenib
1
copanlisib
1
cemiplimab
1
capivasertib
1
camrelizumab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Disease Progression
×
NVP-BKM120
×
Clear all
NCT01737450
2019-06-24
PIK-ORL
Centre Leon Berard
Phase 2
Completed
58 enrolled